Immunotherapy

The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.

More personalized approaches are being developed to treat patients with metastatic disease.

Scoring the big NED often leads to that "Terminator" voice whispering in your ear.

Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

A study pairs an IDO inhibitor with PD-1 checkpoint blockade.

Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO.

Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.

A plan for remembering your loved one when times get tough.

The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.

Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.

The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.

In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.

Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC).

According to a phase II study, an immunotherapy targeting HPV-infected cells led to a one-year survival rate among patients with recurrent metastatic cervical cancer.

In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.

Should patients avoid immunotherapy because of the side effects that have been reported? Dr. Lichtenfeld shares his thoughts.

David McDermott, M.D. discusses new advances made to treat kidney cancer.

An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.